- Home
- ZTEK vs IVVD Comparison
ZTEK vs IVVD Comparison
Compare ZTEK & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- IVVD
- Stock Information
- Founded
- ZTEK 2008
- IVVD 2020
- Country
- ZTEK Canada
- IVVD United States
- Employees
- ZTEK N/A
- IVVD N/A
- Industry
- ZTEK Major Chemicals
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- IVVD Health Care
- Exchange
- ZTEK Nasdaq
- IVVD Nasdaq
- Market Cap
- ZTEK 116.6M
- IVVD 116.8M
- IPO Year
- ZTEK N/A
- IVVD 2021
- Fundamental
- Price
- ZTEK $1.03
- IVVD $0.49
- Analyst Decision
- ZTEK
- IVVD Strong Buy
- Analyst Count
- ZTEK 0
- IVVD 5
- Target Price
- ZTEK N/A
- IVVD $7.11
- AVG Volume (30 Days)
- ZTEK 42.0K
- IVVD 859.7K
- Earning Date
- ZTEK 02-11-2025
- IVVD 11-14-2024
- Dividend Yield
- ZTEK N/A
- IVVD N/A
- EPS Growth
- ZTEK N/A
- IVVD N/A
- EPS
- ZTEK N/A
- IVVD N/A
- Revenue
- ZTEK $29,132.00
- IVVD $11,564,000.00
- Revenue This Year
- ZTEK N/A
- IVVD N/A
- Revenue Next Year
- ZTEK N/A
- IVVD $486.65
- P/E Ratio
- ZTEK N/A
- IVVD N/A
- Revenue Growth
- ZTEK 8.15
- IVVD N/A
- 52 Week Low
- ZTEK $0.50
- IVVD $0.45
- 52 Week High
- ZTEK $1.59
- IVVD $5.20
- Technical
- Relative Strength Index (RSI)
- ZTEK 47.23
- IVVD 30.99
- Support Level
- ZTEK $1.05
- IVVD $0.57
- Resistance Level
- ZTEK $1.16
- IVVD $0.62
- Average True Range (ATR)
- ZTEK 0.09
- IVVD 0.07
- MACD
- ZTEK -0.02
- IVVD -0.01
- Stochastic Oscillator
- ZTEK 10.71
- IVVD 12.05
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.